Updates in Pharmacotherapy for Peri-Operative Anticoagulation Management
|
|
- Brian Cannon
- 5 years ago
- Views:
Transcription
1 Updates in Pharmacotherapy for Peri-Operative Anticoagulation Management
2
3
4 RN [7]1 TL1
5 Slide 4 RN [7]1 Somewhere in your introduction I would also like you to address the CHADS-VASC score, what this is, how it is calculated and what it helps us to determine. Rachel Naida, 5/1/2017 TL1 Done. See next slide Trinh Le, 5/1/2017
6
7 Only for patients with atrial fibrillation Eur Heart J. 2010;31(19):
8
9 RN [2]1 Factor Xa inhibitors rivaroxaban(xarelto ) apixaban(eliquis ) edoxaban(savaysa ) Direct Thrombin Inhibitors dabigatran(pradaxa )
10 Slide 8 RN [2]1 I would like you to make a few separate slides here VKA, 2 - Novel agents 3- LMWH. Also i would like you to briefly talk about each of them and why knowing the pharmacokinetics of each is important to understanding how/why we bridge. Example warfarin half life etc. Rachel Naida, 5/1/2017
11 UFH Heparin LMWH Medication Dosing t ½ Onset of action Clearance Enoxaparin (Lovenox ) Varies mins 1-2 hrs 1 mg/kg SQ q12h 1.5mg/kg SQ q24h Dalteparin(Fragmin ) 100 units/kg SQ q12h 200 units/kg SQ q24h Vitamin-K antagonists (VKA) Warfarin(Coumadin ) hrs Enzymatic degradation 3-5 hrs Renal Individualized hrs hrs Renal
12 Medication A. Fib Dosing t 1/2 Onset of action Clearance Direct oral anticoagulants (DOAC) FactorXa Inhibitors Apixaban(Eliquis ) Rivaroxaban(Xarelto ) Edoxaban(SAVAYSA ) Direct thrombin inhibitors 5mg BID or 2.5 mg BID if 2 of the following: Age 80 years, weight 60 kg, or serum creatinine 1.5 mg/dl 20mg daily w/ meals ~12 hrs 3-4 hrs Renal 5-9 hrs 2-4 hrs Renal 60 mg daily hrs 1-2 hrs Renal Dabigatran(Pradaxa ) 150 mg BID hrs 1 hr Renal DOAC black box warning: use in setting of neuraxialanesthesia raises risk of spinal or epidural hematoma RN2 RN3 RN4
13 Slide 10 RN2 I have deleted argatroban and bivalirudin because they are not DOACs (direct-acting-oral-anticoagulants). They are both iv admin. They are however DTIs as you mentioned. but we do not use them for routine anticoagulation maintenance. Rachel Naida, 5/3/2017 RN3 I have also deleted fodaparinux because it is also not oral. Rachel Naida, 5/3/2017 RN4 You are missing one DOAC!!! (hint it is a Xa inhibitor too! and is new) make sure you find this and include! Rachel Naida, 5/3/2017
14 RN1 TL [2] ACC Expert Consensus Decision Pathway for PeriproceduralManagement of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation (NVAF)
15 Slide 11 RN1 Please put the title of the new guidelines on this slide Rachel Naida, 5/1/2017 TL [2]1 check Trinh Le, 5/1/2017
16
17 HAS-BLED Hypertension(>160 mmhg)* 1 Abnormal renal function 1 Abnormal liver function 1 Prior stroke/ TIA 1 Hx or predisposition of bleeding 1 Labile INR* 1 Elderly (>65 years) 1 Concomitant use of antiplatelet or NSAID * 1 Alcohol or drug use ( 8 drinks/week)* 1 RN [3]1 RN [4]1 TL [3]1 N EnglJ Med 2015; 373:
18 Slide 13 RN [3]1 Please indicate somewhere on this slide that this is the HAS-BLED Score Rachel Naida, 5/1/2017 RN [4]1 Please also make two seperate slides from this - 1. HAS-BLED (on the left) 2. Other risk factors (on the right). Rachel Naida, 5/1/2017 TL [3]1 check Trinh Le, 5/2/2017 RN5 great job highlighting the correctable factors Rachel Naida, 5/3/2017
19 Other Risk Factors Prior bleeding event within 3 months (includes intracranial hemorrhagic) Quantitativeand qualitative platelet abnormality INR aboverange at time of procedure Bleedinghxfrom previous bridging Bleeding hxwithsimilar procedure RN6 N EnglJ Med 2015; 373:
20 Slide 14 RN6 Make sure you understand what is considered a platelet abnormality! What is the quantitive value at which PLT count is likely too low to consider bridging? Rachel Naida, 5/3/2017
21 RN7 Rose Anne et al. Periproceduraland Regional Anesthesia Management with Antithrombotic Therapy Adult Inpatient and Ambulatory Clinical Practice Guideline; University of Wisconsin: 0-13; Aug. 2015
22 Slide 15 RN7 what is considered a simple dental extraction? what would be considered more complex? I think the main point here is that even if we believe the surgery to be considered a "minor" bleed risk we should still be contacting the performing surgeon as well as the provider to get their opinion on surgerys bleed risk. Surgical technique and other factors can also influence bleed risk. Rachel Naida, 5/3/2017
23
24 No ProcedureNo clinicallyimportant or low bleed risk AND no patient related bleed risk factors Yes Procedure with intermediate or high bleed risk Procedure with uncertain risk and presence of patient related risk factors Consider Procedure with no clinicallyimportant or low bleed risk AND presence of patient related risk factors Procedure with uncertain risk ANDabsence of patient related risk factors N EnglJ Med 2015; 373:
25 RN [6]1 Procedural Bleed Risk No clinically important risk Low bleed risk Uncertain,Intermediate, or High bleed risk Whether to Interrupt Time surgery at DOAC interval trough Interrupt Interrupt N EnglJ Med 2015; 373:
26 Slide 18 RN [6]1 Make sure you type this out first (Direct Acting Anticoagulant) before you use the abbreviation. Rachel Naida, 5/1/2017
27
28 RN [5]1 TL [4]1 INR Discontinue prior procedure (days) >3 At least5 N EnglJ Med 2015; 373:
29 Slide 20 RN [5]1 Make sure you can explain why here! Why do we need to measure the INR 5-7 days before? Help the nurses understand the reasoning behind these recommendations rather than just stating the recommendation. Rachel Naida, 5/1/2017 TL [4]1 see notes Trinh Le, 5/2/2017
30 John U. Doherty et al. JACC 2017;69:
31 Timing of last dose before surgery/procedure base on bleed risk and renal function Renal Function RIVAROXABAN t½= 5-9hr (11-13hr for elderly) DABIGATRAN t½= 12-17hr (14-17hr for elderly) APIXAPAN t½= ~12hr (CrCl, ml/min) # Low Risk High Risk Low Risk High Risk Low Risk High Risk >80 >24 h >48 h >24 h >48 h >24 h >48 h >24 h >48 h >36 h >72 h >24 h >48 h >24 h >48 h >48 h >4 days >24 h >48 h <30 Not indicated Not indicated Not indicated Not indicated >36 h * >48h * # CrCl calculated using the Cockcroft-Gault equation with ACTUAL body weight * Apixaban not indicated if CrCl <25 ml/min Post-Op: All agents should be resumed hours after procedure StangierJ, RathgenK, StähleH, Mazur D: Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259 68
32
33 RN [8]1 John U. Doherty et al. JACC 2017;69:
34 Slide 24 RN [8]1 make sure you explain why bridging with LMWH is NOT needed for DOAC patients Rachel Naida, 5/1/2017
35 John U. Doherty et al. JACC 2017;69:
36
37 Medication Dosing Heparin Varies Enoxaparin (Lovenox ) Dalteparin (Fragmin ) Tinzaparin (Innohep ) 1 mg/kg SQ q12h 1.5mg/kg SQ q24h 100 units/kg SQ q12h 200 units/kg SQ q24h 175 IU/kg once daily
38
39
40 BridgeAnticoag American College of Cardiology
41 RN10 RN9 PMH: A. fib T2DM Hypogonadism Glaucoma Macular degeneration Esophagitis CKD OSA COPD Lung cancer Obesity Hypercholesterolemia Prior stroke Erosive gastritis Peripheral Vascular Disease
42 Slide 31 RN9 When was pre-procedure INR drawn in relation to when procedure was performed? Rachel Naida, 5/3/2017 RN10 Another question - when should ASA be stopped before a surgery?!!!!! I see ASA on his list here! Rachel Naida, 5/3/2017
43 Patient Case #1 Aspirin 81 mg tablet Lantus Solostar 100u/mL Allopurinol 100 mg tablet Gabapentin 300 mg capsule Furosemide 40 mg tablet Januvia 50 mg tablet Levothyroxine 25 mcg tablet Spiriva 18 mcg capsule Nitroglycerin 0.4 mg tablet Multivitamin Medications Warfarin 5 mg tablet Omeprazole 40 mg DR capsule Glipizide 5 mg tablet Rosuvastatin 40 mg tablet Celexa 40 mg tablet Co-enzyme Q mg capsule Diltiazem 120 mg ER capsule Aldactone 25 mg tablet Valsartan 40 mg tablet KrillOil
44 Height Weight BP 66 Inches 262 pounds(lbs), 191 kg 106/40 SrC CrCl HAS-BLED Procedural Bleeding risk CHAD-VASc INR prior surgery Intermediate 6 7 days: days: 4.2 Day of: 2.7 Lab Value Normal White blood cell count (x1000/ul) Red Blood Cell Count (mil/ul) Hemoglobin (gm/dL) Hematocrit (%) Neutrophils (%) Platelet Count (x1000/uL) Lymphocytes (%)
45 HAS-BLED Hypertension(>160 mmhg)* 1 Patients Factors Abnormal renal function 1 1 Abnormal liver function 1 Prior stroke/ TIA 1 1 Hx or predisposition of bleeding 1 Labile INR* 1 Elderly (>65 years) 1 1 Concomitant use of antiplatelet or NSAID * 1 1 Alcohol or drug use ( 8 drinks/week)* 1 Total Score 4 CHADVASc CHF 1 HTN 1 Patient Factors Age Diabetes 1 1 Stroke/ TIA Hx 2 2 Vascular disease Age Sex (female) Total Score 6
46 HAS-BLED score: 4 Intermediate (colonoscopy) Yes ~5 days before (if INR therapeutic) Likely YES LMWH Consult with proceduralist, likely hours post
47
48
49 Patient case #2 Hydrochlorothiazide 12.5mg cap Toprol XL 200mg Multivitamin Lisinopril 40mg Aspirin81mg Warfarin 3mg Medications Paxil 10mg, 20mg Trazodone 50mg Furosemide 40mg Vitamin D3 2,000 IU Fish Oil Lipitor 80mg
50 Height Weight BP 59.5 Inches 148 pounds(lbs), 67 kg 144/68 SrC CrCl HAS-BLED Procedural Bleeding risk CHAD-VASc INR prior surgery Intermediate 6 Lab Value Normal White blood cell count (x1000/ul) Red Blood Cell Count (mil/ul) Hemoglobin (gm/dL) Hematocrit (%) Neutrophils (%) Platelet Count (x1000/uL) Lymphocytes (%)
51 HAS-BLED Patients Factors Hypertension(>160 mmhg)* 1 1 Abnormal renal function 1 Abnormal liver function 1 Prior stroke/ TIA 1 Hx or predisposition of bleeding 1 Labile INR* 1 Elderly (>65 years) 1 1 Concomitant use of antiplatelet or NSAID * 1 1 Alcohol or drug use ( 8 drinks/week)* 1 Total Score 3 CHADVASc Patient Factors CHF 1 1 HTN 1 1 Age Diabetes 1 Stroke/ TIA Hx 2 Vascular disease Age Sex (female) 1 1 Total Score 6
52 HAS-BLED score: 3 Intermediate (colonoscopy) Yes ~5 days before (if INR therapeutic) Likely NO
53
54 Patient Case #3 Meclizine12.5 mg Proscar 5mg Norvasc 2.5mg Coumadin 5mg Lisinopril 40mg Hytrin5mg Prevacid Medications Actos15mg Celexa 20mg Simvastatin 10mg Osteo- bi flex tablet Saw palmetto Fish oil Ocuvite
55 Height Weight BP 70.5 Inches pounds(lbs), 84 kg 138/70 SrC CrCl HAS-BLED Procedural Bleeding risk CHAD-VASc INR prior surgery Intermediate 4 Lab Value Normal White blood cell count (x1000/ul) Red Blood Cell Count (mil/ul) Hemoglobin (gm/dL) Hematocrit (%) Neutrophils (%) Platelet Count (x1000/uL) Lymphocytes (%)
56 HAS-BLED Patients Factors Hypertension(>160 mmhg)* 1 1 Abnormal renal function 1 Abnormal liver function 1 Prior stroke/ TIA 1 Hx or predisposition of bleeding 1 Labile INR* 1 Elderly (>65 years) 1 1 Concomitant use of antiplatelet or NSAID * 1 Alcohol or drug use ( 8 drinks/week)* 1 Total Score 2 CHADVASc CHF 1 Patient Factors HTN 1 1 Age Diabetes 1 1 Stroke/ TIA Hx 2 Vascular disease 1 Age Sex (female) 1 Total Score 4
57 HAS-BLED score: 3 Intermediate (colonoscopy) Yes ~5 days before (if INR therapeutic) NO
58 PMH: A. Fib TIA Hyperlipidemia GOUT Abnormal liver function HTN PVD Polyneuropathy CAD T2DM CKD Diabetic foot ulcer Obesity CHF
59 Patient case #4 Metoprolol tartrate 100mg Apixaban 5 mg BID Omeprazole 40mg DR Losartan 100mg Furosemide 20mg Allopurinol 300mg Lipitor 80mg Medications Diltiazem 240 mg Er Metformin 500mg ER Aspirin 81mg Docusate sodium 100mg Vitamin B mcg Tylenol 325mg Amlactin 12% cream
60 Height Weight BP 69.5 Inches pounds(lbs), 119 kg 132/60 SrC CrCl HAS-BLED Procedural Bleeding risk CHAD-VASc INR prior surgery Low 8 Lab Value Normal White blood cell count (x1000/ul) Red Blood Cell Count (mil/ul) Hemoglobin (gm/dL) Hematocrit (%) Neutrophils (%) Platelet Count (x1000/uL) Lymphocytes (%)
61 HAS-BLED Patients Factors Hypertension(>160 mmhg)* 1 1 Abnormal renal function 1 1 Abnormal liver function 1 1 Prior stroke/ TIA 1 1 Hx or predisposition of bleeding 1 Labile INR* 1 Elderly (>65 years) 1 1 Concomitant use of antiplatelet or NSAID * 1 1 Alcohol or drug use ( 8 drinks/week)* 1 Total Score 6 CHADVASc Patient Factors CHF 1 1 HTN 1 1 Age Diabetes 1 1 Stroke/ TIA Hx 2 2 Vascular disease Age Sex (female) Total Score 8
62 HAS-BLED score: 6 Low (skin biopsy) Yes 24 hours before procedure NO
63
Managing Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More information4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationPeri-Procedural Management of Antithrombotic Agents
u Peri-Procedural Management of Antithrombotic Agents An Integrated Care Pathway of the Collaborative Care Network Subject Matter Experts: Will Maxted, MD Veronica Kerner, PharmD Pathway Custodian: Pat
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationTo Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin
To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationManagement of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY
ANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-236-L01-P 0.1 CEU/1.0 hr Activity Type: Application-Based Learning Objectives for Pharmacists: Upon
More informationFibs and Flutters: The Heart of the Matter
Fibs and Flutters: The Heart of the Matter Anita Ralstin, CNP By the Numbers Atrial Fibrillation Hospital Discharges /quarter for 2012 -- 116,500 Average Length of Stay 4 days Projected that 20% of those
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationDirect oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
J Thromb Thrombolysis (2016) 42:573 578 DOI 10.1007/s19-016-1410-z Direct oral anticoagulant use and the incidence of in the very elderly with atrial fibrillation Fatima Khan 1,2 Hans Huang 2 Yvonne H.
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationUpdate in Perioperative Anticoagulation and Antiplatelet management
Update in Perioperative Anticoagulation and Antiplatelet management Grand Rounds October 31, 2014 Brooke Hall, MD Steve Kornfeld, MD Bruce McLellan, MD Nothing to disclose Objectives Describe the updates
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationAnticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics
MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationMEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW
MEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW Presented by: David B. Coriale RPh. Pharm D BCPS Clinical Pharmacy Manger Oneida Healthcare Oneida, NY WWW.HEALTHUNITS.COM Presentation John is a
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationCASUISTIEK: DOACS. Kop 1/02/2018. Voet 1 INLEIDING INLEIDING. Klassieke OAC. DOACs CORRECT DOSING. Prof. Stephane Steurbaut, PharmD, PhD
INLEIDING CASUISTIEK: DOACS Prof. Stephane Steurbaut, PharmD, PhD Klinische Universitaire Farmacie Ziekenhuizen - Transmurale 27-1-2018 Zorg 2 2 INLEIDING Klassieke OAC DOACs COECT DOSING Indication VTE
More informationChange from lovenox to pradaxa
P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More information4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,
Not intended for medical clearance Identify, document, and evaluate health conditions Medication Management Stratify Risks Optimize conditions within context of surgical illness Recommend measures that
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationAnticoagulation in Atrial Fibrillation An Asian Perspective. Dr Yap Lok Bin Cardiologist
Anticoagulation in Atrial Fibrillation An Asian Perspective Dr Yap Lok Bin Cardiologist Structure Atrial Fibrillation and OACs among Asians Warfarin Our experience of anticoagulants Risk Scoring Strategies
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationMedications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationShared Decision Making. Eva Kline-Rogers, MS,NP, AACC Co-Director, MCORRP Cardiovascular Nurse Practitioner
Shared Decision Making Eva Kline-Rogers, MS,NP, AACC Co-Director, MCORRP Cardiovascular Nurse Practitioner Disclosures ACF Board of Directors Consultant Janssen Pharmaceuticals Consultant American Association
More informationFamily Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008)
1 Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More information